Cargando…

Secukinumab lowers expression of ACE2 in affected skin of patients with psoriasis

Detalles Bibliográficos
Autores principales:	Krueger, James G., Murrell, Dedee F., Garcet, Sandra, Navrazhina, Kristina, Lee, Patricia C., Muscianisi, Elisa, Blauvelt, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834246/ https://www.ncbi.nlm.nih.gov/pubmed/33002515 http://dx.doi.org/10.1016/j.jaci.2020.09.021

Ejemplares similares

Secukinumab in Generalized Pustular Psoriasis
por: Madanagobalane, Shraddha
Publicado: (2018)

Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
por: Bagel, Jerry, et al.
Publicado: (2018)

Secukinumab treatment showed improved quality of life in patients with chronic plaque psoriasis in Australia: Results from the HOPE study
por: Foley, Peter, et al.
Publicado: (2022)

Widespread Superficial Dermatophytosis in Patient on Secukinumab for Treatment of Chronic Plaque Psoriasis
por: Neema, Shekhar, et al.
Publicado: (2019)

Successful secukinumab treatment in focal segmental glomerulosclerosis associated with plaque psoriasis
por: Cao, Zhiqiang, et al.
Publicado: (2022)

Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Blauvelt, Andrew, et al.
Publicado: (2023)

Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52‐week results from a double‐blind phase 3b trial (CLARITY)
por: Bagel, J., et al.
Publicado: (2020)

Should biologics for psoriasis be interrupted in the era of COVID-19?
por: Lebwohl, Mark, et al.
Publicado: (2020)

Arthropathic psoriasis complicated by a paradoxical reaction in the form of erythrodermic psoriasis following adalimumab and by an allergic reaction following infliximab which was successfully managed with secukinumab
por: Tichy, Martin
Publicado: (2019)

Secukinumab: Rapid Efficacy in Psoriasis After Primary Failure With Ustekinumab and Adalimumab
por: Okita, Aline Lissa, et al.
Publicado: (2020)

A case of twins affected by psoriasis, psoriatic arthritis and autism: Five years of efficacious and safe treatment with Secukinumab
por: Bernardini, Nicoletta, et al.
Publicado: (2022)

Combining secukinumab and apremilast to successfully treat refractory psoriatic skin and joint disease: A novel approach
por: Nisar, Muhammad K.
Publicado: (2019)

Evaluation of skin of color content in Skin Research and Technology
por: Sun, Mary, et al.
Publicado: (2022)

Successful use of secukinumab in pustular psoriasis
por: Yeung, Jensen, et al.
Publicado: (2016)

Mental health, insomnia and suicidal ideation during treatment with apremilast
por: Cowan, Timothy L., et al.
Publicado: (2022)

Excellent Response to Secukinumab in Treatment Resistant Impetigo Herpetiformis
por: Neema, Shekhar, et al.
Publicado: (2022)

Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Fitzgerald, Timothy, et al.
Publicado: (2023)

Embracing diversity in dermatology: Creation of a culture of inclusion in dermatologic publishing
por: Murase, Jenny E., et al.
Publicado: (2021)

The International Reach of the International Journal of Women's Dermatology and the Women's Dermatologic Society
por: Murrell, Dedee F., et al.
Publicado: (2021)

Heralding change within dermatology: Response of the International Journal of Women’s Dermatology (IJWD) to the twin pandemic of racism
por: Murase, Jenny E., et al.
Publicado: (2021)

Profile of secukinumab in the treatment of psoriasis: current perspectives
por: Roman, Michael, et al.
Publicado: (2015)

Secukinumab in the treatment of psoriasis: patient selection and perspectives
por: Yang, Eric J, et al.
Publicado: (2018)

Secukinumab in the Treatment of Plaque Psoriasis in Patients with Malignancy
por: Gambardella, Alessio
Publicado: (2019)

Real-world data on secukinumab use for psoriatic arthritis and ankylosing spondylitis
por: Elliott, Ashley, et al.
Publicado: (2019)

Normocomplementaemic urticarial vasculitis: effective treatment with omalizumab
por: de Brito, Marianne, et al.
Publicado: (2018)

Psoriasis and osteoporosis: a literature review
por: Wi, Dohyen, et al.
Publicado: (2022)

34346 Pooled safety analysis of respiratory tract infections, including COVID-19, in psoriasis patients treated with secukinumab
por: Schulze-Koops, Hendrik, et al.
Publicado: (2022)

Shedding light on the impact of hidradenitis suppurativa on women and their families: A focus of the International Journal of Women's Dermatology
por: Revankar, Rishab, et al.
Publicado: (2021)

Secukinumab in severe COVID-19 pneumonia: Does it have a clinical impact?
por: Hasan, Md. Jahidul, et al.
Publicado: (2021)

Reply to: “Biologics for psoriasis during COVID-19 outbreak”
por: Murrell, Dedee F., et al.
Publicado: (2020)

Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab
por: Morita, Akimichi, et al.
Publicado: (2020)

Efficacy of Secukinumab for Plaque Psoriasis in a Patient on Hemodialysis
por: Ikuma, Daiuske, et al.
Publicado: (2019)

Secukinumab for psoriasis in a patient with familial Mediterranean fever
por: Cannavò, Serafinella P., et al.
Publicado: (2019)

Secukinumab for Psoriasis in Obese Patients: Minireview and Clinical Experience
por: Tiberio, Rossana, et al.
Publicado: (2019)

Behandlung der Psoriasis mit Secukinumab: Praxisrelevante Hinweise
por: Körber, Andreas, et al.
Publicado: (2021)

Secukinumab for the Treatment of Psoriasis in Pediatrics: Patient Selection and Acceptability
por: Narbutt, Joanna, et al.
Publicado: (2023)

Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months
por: Blauvelt, Andrew, et al.
Publicado: (2021)

ACE2 mutation might explain lower COVID-19 burden in malaria endemic areas
por: De, Auley, et al.
Publicado: (2021)

A Case of Moderate Hidradenitis Suppurativa and Psoriasis Treated with Secukinumab
por: Giuseppe, Pistone, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5bimv9r0i4sqma6jku00i5615l